1. Home
  2. STRS vs PLX Comparison

STRS vs PLX Comparison

Compare STRS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

HOLD

Current Price

$24.59

Market Cap

168.1M

Sector

Real Estate

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$1.79

Market Cap

142.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRS
PLX
Founded
1992
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.1M
142.3M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
STRS
PLX
Price
$24.59
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
14.2K
555.0K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$31,912,000.00
$61,840,000.00
Revenue This Year
N/A
$14.29
Revenue Next Year
N/A
$16.65
P/E Ratio
N/A
$26.20
Revenue Growth
N/A
35.41
52 Week Low
$15.10
$1.32
52 Week High
$26.30
$3.10

Technical Indicators

Market Signals
Indicator
STRS
PLX
Relative Strength Index (RSI) 64.56 47.15
Support Level $23.95 $1.74
Resistance Level $26.30 $1.87
Average True Range (ATR) 0.93 0.09
MACD 0.04 0.01
Stochastic Oscillator 72.97 59.46

Price Performance

Historical Comparison
STRS
PLX

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations. Real Estate Operations segment encompasses activities associated with entitlement, development, and sale of real estate. Leasing Operations segment involves leasing of commercial space at retail and mixed-use properties and residences in multi-family properties that company developed. Majority of revenue is from Real Estate Operations.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: